catalyst calendar
/
← Catalyst calendar

OBIO biotech catalysts & pipeline

ORCHESTRA BIOMED HOLDINGS INC · Data as of 2026-10-25

Upcoming catalysts

Atrioventricular Interval Modulation Therapy ("AVIM Therapy") — Topline data

2026

We expect 2026 will be a landmark year for Orchestra BioMed, with target completion of enrollment in the BACKBEAT study and primary endpoint results data to follow thereafter, given that the primary efficacy and safety endpoints are measured at three months follow-up.
Source filing

Atrioventricular Interval Modulation Therapy ("AVIM Therapy") — Conference presentation

Q2 2027

Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
Source filing

Explore the free biotech catalyst calendar